Top Biotech Companies in Singapore (91)
Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. We help our customers #SimplifyProgress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are #PartOfTheSolution in the fight against diseases worldwide. With innovative laboratory instruments and consumables, the our Lab Products & Services division focuses on laboratories performing...
Sartorius's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent market analyses repeatedly characterize Sartorius as a top‑tier leader in single‑use bioprocessing, particularly in single‑use bioreactors, bags/assemblies, and integrated upstream platforms. Broad scale from bench to 2,000‑L, a large installed base, and continued capacity expansions reinforce this position.
Strong Revenue Growth: Company disclosures indicate sales grew 7.6% in constant currencies in 2025 to about €3.54 billion, with Q1 2026 up 7.5% and full‑year 2026 guidance of 5–9% growth. Order intake recovery from late 2024 and momentum in Bioprocess Solutions underpin this trend.
Profitability: Underlying EBITDA increased faster than sales in 2025, with margin near 30%, and management expects robust margins into 2026. Improving cash generation and recurring consumables contribute to sustained profitability.
At KROSSLINKER, we innovate and transform Aerogel for challenging insulation applications. Our first product aims to serve the cold-chain biopharma packaging industry by protecting temperature-sensitive pharmaceuticals, precious biologics, and vaccines throughout their shipping journey with our transformative technology.
MMR Consulting Inc. and its dedicated team of experienced consultants are committed to delivering high quality, robust solutions for the Pharmaceutical and Biotechnology industries. Our expertise includes Engineering (Process, Automation, Facilities), Capital Project Management of large/complex projects and programs, Commissioning Qualification Validation, and GMP Compliance services.
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health...
ReSync coordinates labs, data, and AI models on one platform. Stop wrangling with emails and spreadsheets – find data and make decisions twice as fast.
Twenty years ago, we pioneered the world's first clear aligners. Since then, we have continuously innovated with new products and technologies that are revolutionizing treatments for doctors and their patients. Invisalign clear aligners and the iTero Intraoral scanner help dental professionals achieve the clinical results they expect and deliver effective, advanced dental options to their patients. Helping change millions of lives,...
Align Technology's Top Stability & Growth Strengths
Strong Market Position & Advantage: Invisalign is broadly viewed as the clear leader in doctor‑directed clear aligners, reinforced by a large trained‑doctor base and an integrated digital workflow. Record Q4/FY 2025 volumes and revenue, alongside industry characterization as the market leader, support advantage durability.
Market Expansion: International regions (EMEA, Latin America, APAC) are cited as driving year‑over‑year volume growth, with contributions from teen/kids and adult segments and growing DSO/OSO channels. Continued gains outside North America align with guidance for additional growth into 2026.
Innovation-Driven Growth: An integrated platform spanning Invisalign, iTero scanners, and exocad software underpins a closed‑loop workflow that encourages adoption. Ongoing iTero Lumina upgrades and plans for directly 3D‑printed retainers/attachments in 2026 indicate a pipeline that can sustain future growth.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture...
Thermo Fisher Scientific's Top Stability & Growth Strengths
Strong Market Position & Advantage: Thermo Fisher’s scale and breadth—largest revenue in 2025 (~$44.6B), leadership across a moderately consolidated tools market, and a top‑tier market value—support clear category leadership. Third‑party benchmarking and peer comparisons (e.g., relative to Danaher) reinforce its platform advantage.
Diversified Revenue Streams: A broad, integrated portfolio spanning instruments, consumables, diagnostics, distribution, and biopharma services (PPD, Patheon) drives multiple revenue engines and customer stickiness. Recurring consumables/services and distribution contribute steady mix that helps smooth cycles.
Innovation-Driven Growth: Recent product launches (e.g., Glacios 3 Cryo‑TEM, TSQ Certis) and the NVIDIA collaboration to accelerate AI‑enabled and increasingly autonomous lab systems indicate continued innovation momentum. These initiatives position the platform to capture next‑gen workflow demand.
Founded in 1996, PSC Biotech Corporation was created with the vision of providing life science companies unmatched support. To date, PSC Biotech Corporation now serves 1000 clients in more than 35 countries worldwide through professional services consulting, cloud-based software solutions, pharmaceuticals contract manufacturing, life science investment consulting, and metrology services. PSC Biotech Corporation has six unique divisions within the parent company...
We are a molecular life science company dedicated to advancing human health through innovation. By designing and building breakthrough molecular platforms that are both accessible and best-in-class, One BioMed is providing biomedical researchers and clinicians with unprecedented access to cutting-edge tools.
AB Enzymes is an industrial biotech company specialized in enzymes and their applications. The company is part of Associated British Foods and represented worldwide. Our offices are located in Brazil, China Germany, Finland, Singapore and USA. Our products range from food grade enzymes for baking and beverages, grains and vegetable oil seeds processing, to enzymes for animal feed and technical applications:...
Nutrition Technologies (“NT”) researches, manufactures and supplies sustainable agricultural inputs (animal feed ingredients, biofertilisers and biological agents). NT uses its unique proprietary biotechnology and Black Soldier Fly Larvae (BSFL) rearing process to recycle nutrients from agricultural and food processing by-products. Their insect-based products help feed the growing agriculture and feed industries around the world. These products are suitable for application...
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Learn...
X-ZELL is an award-winning medical technology start-up specialising in next-generation cytology. Cytology – or cytopathology – is the science of diagnosing diseases by examining single atypical cells or cell clusters. X-ZELL has developed a plug-and-play solution for the detection, visualization and digitization of these phenomena in minimally invasive body liquids. Slotting seamlessly into clinical routine, it does not require complex...
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
Vulcan Augmetics is building a distribution and data ecosystem for the $156BN biosignal sensor market. Using ML powered wireless EMG sensors with deep learning networks, our goal is to become the gateway between hardware and humanity, providing high fidelity biodata and feedback so that healthcare professionals can make better decisions for their patients, and everyday users can control their devices...
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and...
Elekta's Top Stability & Growth Strengths
Strong Market Position & Advantage: Elekta is a top-tier radiotherapy vendor with category leadership in cranial stereotactic radiosurgery and a notable presence in high-field MR-guided therapy, reinforcing durable competitive standing. Recognition for oncology information systems further supports its positioning in cancer centers.
Innovation-Driven Growth: Recent launches such as Elekta Evo and the Elekta ONE software suite, alongside continued advancement of Unity MR‑Linac workflows, indicate a pipeline that is aiding orders and improving mix. These innovations underpin adaptive and image‑guided therapy strategies across the portfolio.
Resilient & Sustainable Growth: Book‑to‑bill ratios above 1.0 and low single‑digit constant‑currency sales growth point to steady underlying expansion. Improving adjusted margins in recent quarters suggest operational gains despite macro headwinds.
Mobcoder is a global technology company specializing in AI development and innovative solutions. Since 2014, we've launched over 300 apps, empowering businesses across various industries and locations.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
Amgen's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.
Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.
Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.
We are a bunch of highly experienced doctors, technologists, insurance experts and managed care practitioners who believe that we can use technology to improve the quality of Asian healthcare while lowering costs. We also know what works in Asia, and we brought best-in-class technologies from around the world on to one platform to make that belief a reality. We get...
